{"product_id":"neo-bcg-matrix","title":"(NEO) NeoGenomics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis NeoGenomics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The content shown on this page is a real preview of the actual report, so you can review the format and analysis before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma Services oncology biomarker trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeoGenomics, Inc. Pharma Services is a Star: it supports discovery through commercialization, and oncology drug development stayed one of the fastest-growing CRO outsourcing areas through end-2025. The unit benefits from durable demand in biomarker-driven trials, where precision oncology keeps lifting trial complexity and spend. With meaningful scale inside NeoGenomics, it is a clear growth engine, not a niche add-on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMolecular oncology testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMolecular oncology testing is a Star for NeoGenomics, Inc. because DNA and RNA-based panels sit at the center of precision oncology and keep shifting demand toward deeper, more complex testing. In FY2025, this category remained a core growth engine as the company pushed higher-value next-generation sequencing and fusion testing across its oncology menu. That mix supports brand strength, pricing power, and share gains in a fast-growing market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLiquid biopsy and ctDNA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLiquid biopsy and ctDNA are a clear Star for NeoGenomics, Inc., because the segment is growing fast and adoption is still climbing. Inivata-linked capabilities strengthen its reach in MRD and early relapse detection, where ctDNA can be measured at very low variant allele fractions, often below 0.1%. The market is still expanding, so this line has high growth and rising strategic value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMRD-focused oncology assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMRD-focused oncology assays are a high-growth niche because they track tiny cancer traces after treatment, not just at diagnosis. In a market where MRD use is expanding across solid tumors and blood cancers, NeoGenomics, Inc. has flagged this as a core future-growth platform, with the biggest value in monitoring response and spotting recurrence earlier.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonitors treatment response\u003c\/li\u003e\n\u003cli\u003eTracks recurrence risk\u003c\/li\u003e\n\u003cli\u003eExpands beyond diagnosis\u003c\/li\u003e\n\u003cli\u003eSupports NeoGenomics growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntegrated multi-modality cancer testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeoGenomics runs 5 testing lanes in one oncology platform: molecular, cytogenetic, FISH, flow, and pathology. That breadth is a clear Star trait, because hospitals and oncologists can keep one vendor across the full workup, and pharma partners get cleaner trial and companion-diagnostic support.\u003c\/p\u003e\n\u003cp\u003eThe integrated menu helps raise retention and cross-sell rates across the testing chain, which matters in a fragmented cancer testing market. One platform, more touchpoints, and fewer handoffs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 modalities under one platform\u003c\/li\u003e\n\u003cli\u003eStronger hospital and oncologist stickiness\u003c\/li\u003e\n\u003cli\u003eBetter cross-sell across test types\u003c\/li\u003e\n\u003cli\u003eUseful for pharma trial support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeoGenomics’ Precision Oncology Engines Are Firing on All Cylinders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeoGenomics, Inc. Stars are its Pharma Services, molecular oncology, liquid biopsy\/ctDNA, and MRD assays: all sit in fast-growing precision oncology niches and support both clinical testing and pharma demand. The company also benefits from an integrated 5-lane platform, which improves stickiness and cross-sell across oncology workflows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma Services\u003c\/td\u003e\n\u003ctd\u003eDrug development demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular oncology\u003c\/td\u003e\n\u003ctd\u003eNGS and fusion growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquid biopsy\/ctDNA\u003c\/td\u003e\n\u003ctd\u003eFast adoption, MRD use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated platform\u003c\/td\u003e\n\u003ctd\u003e5 testing lanes, higher retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eNeoGenomics BCG Matrix maps its testing portfolio by growth and share, guiding invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG matrix for NeoGenomics, Inc. that quickly spots growth and drag areas for faster portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for NeoGenomics, Inc. data, helping verify assumptions fast and support confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Services core lab network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical Services is NeoGenomics’ mature cash engine, with FY2024 revenue of about $615 million and a national network serving hospitals, reference labs, pathologists, and oncologists. Growth is slower than newer tests, but demand is steady and the platform stays essential to recurring oncology testing. That makes it a classic Cash Cow: lower growth, strong scale, and dependable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFISH testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFISH testing is a mature oncology assay, so demand is steadier than next-generation molecular testing. For NeoGenomics, Inc., that makes it a Cash Cow: lower-growth, recurring lab volume that still supports revenue. The test stays useful for targeted cancer markers, so it keeps paying even as newer platforms take share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCytogenetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCytogenetics is a legacy cash cow for NeoGenomics, with steady demand in cancer diagnostics and long-used lab workflows. It is a mature business, so it is more about supporting stable cash flow than fast growth. That fits a BCG Cash Cow profile: low expansion, but dependable contribution to the company’s operating base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFlow cytometry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFlow cytometry is a Cash Cow for NeoGenomics, Inc. because it is a core oncology and hematology test used in routine clinical workflows, so demand is steady and repeatable. The service supports margins through high utilization, even if growth is modest versus newer molecular tests. \u003c\/p\u003e\n\u003cp\u003eIn NeoGenomics, Inc.’s 2025 reporting, this kind of mature lab volume helps offset more volatile assay lines and keeps the base business stable. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady oncology test demand\u003c\/li\u003e\n\u003cli\u003eEmbedded in routine workflows\u003c\/li\u003e\n\u003cli\u003eModest growth, reliable revenue\u003c\/li\u003e\n\u003cli\u003eSupports lab margin stability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eImmunohistochemistry and morphologic analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunohistochemistry and morphologic analysis are core cancer-pathology tools at NeoGenomics, Inc., helping classify tissue and guide diagnosis in routine tumor workups. They fit a mature market, so the service line is more of a steady cash generator than a high-growth bet. Their place in the lab flow also supports efficient throughput and repeat volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFoundational in cancer diagnosis\u003c\/li\u003e\n\u003cli\u003eHigh routine-use volume\u003c\/li\u003e\n\u003cli\u003eOperationally efficient lab fit\u003c\/li\u003e\n\u003cli\u003eMature, cash-flow style segment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeoGenomics’ Cash Cows Keep the Oncology Lab Engine Running\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeoGenomics, Inc.’s Cash Cows are its mature clinical lab lines: Clinical Services generated about $615 million in FY2024 revenue, while FISH, cytogenetics, flow cytometry, and immunohistochemistry keep steady repeat volume. These are low-growth but essential oncology tests, so they support cash flow and lab utilization more than expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eFY2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Services\u003c\/td\u003e\n\u003ctd\u003eCore cash engine\u003c\/td\u003e\n\u003ctd\u003e$615 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFISH, cytogenetics, flow, IHC\u003c\/td\u003e\n\u003ctd\u003eRecurring mature volume\u003c\/td\u003e\n\u003ctd\u003eSteady demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eNeoGenomics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact NeoGenomics, Inc. BCG Matrix document you’ll receive after purchase. The full file is the same professionally formatted report—no sample pages, no watermarks, and no hidden content. Once purchased, it’s instantly ready for download, editing, printing, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy manual karyotyping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy manual karyotyping at NeoGenomics, Inc. is a low-growth, low-share Dog. It is slower and less scalable than NGS-based diagnostics, so volume can slip as labs shift to faster molecular tests. NeoGenomics, Inc. still offers the method, but the strategic weight is limited versus higher-growth genomic assays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandalone routine pathology workups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandalone routine pathology workups are a Dogs business for NeoGenomics, Inc. because morphology-only tests are highly commoditized and face heavy price pressure. They lack the deeper clinical differentiation of NeoGenomics, Inc.’s oncology menu, so pricing power is weak and growth tends to stay thin. In BCG terms, this is a low-share, low-growth area that usually earns little strategic capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume single-gene assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLow-volume single-gene assays fit NeoGenomics, Inc.'s Dogs bucket: they are low-growth, low-share tests that are being squeezed by broader multiplex panels. These small assays usually add little incremental margin and face heavy price pressure from larger lab menus. As panels keep taking share, this line looks increasingly isolated and hard to scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall non-core lab footprints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeoGenomics, Inc.'s small non-core lab footprints fit the Dogs box because they usually sit outside the main U.S. oncology network and are hard to scale. If sample volumes stay thin, these sites add little margin and can drain cash instead of supporting growth. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow volume limits fixed-cost absorption\u003c\/li\u003e\n\u003cli\u003eWeak strategic fit outside core oncology\u003c\/li\u003e\n\u003cli\u003eHigher risk of cash drag\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn 2025, this kind of footprint matters less than the core lab base, since oncology testing scale drives better utilization and return on invested capital. Small sites only help if they lift throughput fast; otherwise, they are maintenance costs, not growth assets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCustom one-off research projects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCustom one-off research projects fit the Dog profile because NeoGenomics, Inc. must spend technical labor on ad hoc testing that is hard to standardize and rarely repeats. When demand is irregular, these jobs drain lab capacity but do not build durable share or recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow repeat volume\u003c\/li\u003e\n\u003cli\u003eHard to standardize\u003c\/li\u003e\n\u003cli\u003eConsumes technical resources\u003c\/li\u003e\n\u003cli\u003eNo durable share gain\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeoGenomics’ Dogs: Legacy Tests Draining Capital, Not Growing Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeoGenomics, Inc.'s Dogs are legacy, low-share, low-growth tests: manual karyotyping, morphology-only workups, single-gene assays, small non-core sites, and ad hoc research projects. These lines face weak pricing power, thin repeat volume, and poor scale, so they absorb capacity without much margin lift. In 2025, capital should stay with higher-growth oncology panels and NGS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog area\u003c\/th\u003e\n\u003cth\u003eWhy it lags\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy tests\u003c\/td\u003e\n\u003ctd\u003eLow growth, commoditized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmall sites\/projects\u003c\/td\u003e\n\u003ctd\u003eLow volume, cash drag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital pathology and AI analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDigital pathology and AI analytics are a clear Question Mark for NeoGenomics, Inc. because the segment is scaling fast in cancer diagnostics, but NeoGenomics’ share is still small. Its pathology workflow gives it a real route in, yet the market needs more software, data, and lab investment before it can turn into a cash generator. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurope expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurope is a question mark for NeoGenomics, Inc.: the business is present there, but scale is still far below the U.S. The region has real upside, with Europe seeing roughly 4.7 million new cancer cases a year and rising demand for oncology testing. Still, NeoGenomics’ competitive position is early, so growth is possible but not yet proven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsia expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAsia is a big question mark for NeoGenomics, Inc. because the region carries about 60% of global cancer cases, so the long-run oncology testing pool is huge. \u003c\/p\u003e\n\u003cp\u003eNeoGenomics has a footprint there, but its share is still small versus stronger local and global rivals, which keeps revenue capture limited. \u003c\/p\u003e\n\u003cp\u003eIf it can win on turnaround time, payer access, and lab reach, Asia could shift from question mark to star; if not, growth stays optional. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInivata alliance commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeoGenomics’ Inivata alliance sits in the question mark bucket because it opens a path into liquid biopsy, but adoption is still early and scale is not proven. The commercial upside is real, yet the business has not shown dominant traction or a clear near-term cash engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigh growth potential\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLow certainty on scale\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eEarly commercialization only\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew companion diagnostic launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew companion diagnostics are a clear Question Mark for NeoGenomics, Inc.: they can ride with targeted cancer drugs, but each assay still needs adoption by oncologists and pharma partners. The opportunity is real, yet volume often starts small and stays uneven until a launch gains trust and repeat use.\u003c\/p\u003e\n\u003cp\u003eThat makes returns hard to predict in the early phase, even when the drug pipeline is strong. In NeoGenomics, Inc.’s case, these launches can win work, but the business only shifts toward a Star once test volumes and reimbursement both mature.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong drug tie-ins, but slow adoption.\u003c\/li\u003e\n\u003cli\u003ePartnership wins do not ensure volume.\u003c\/li\u003e\n\u003cli\u003eEarly launches stay cash-uncertain.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeoGenomics’ Global Growth Bets: Huge Demand, Early Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeoGenomics, Inc. question marks are high-growth bets with low current share: digital pathology and AI, Europe, Asia, Inivata, and new companion diagnostics. Asia holds about 60% of global cancer cases, and Europe sees about 4.7 million new cases a year, but NeoGenomics’ scale there is still early.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia\u003c\/td\u003e\n\u003ctd\u003eHuge demand, small share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEurope\u003c\/td\u003e\n\u003ctd\u003e4.7M cases, early scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234723537161,"sku":"neo-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/neo-bcg-matrix.webp?v=1785726090","url":"https:\/\/dcfanalyst.com\/products\/neo-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}